{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:46:03Z","timestamp":1787237163682,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-025-03474-8","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T12:34:40Z","timestamp":1749126880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Aging-dependent change in Th17 and cytokine response in multiple sclerosis"],"prefix":"10.1186","volume":"22","author":[{"given":"Wen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Revu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy J.","family":"McGeachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"3474_CR1","doi-asserted-by":"publisher","first-page":"1207617","DOI":"10.3389\/fneur.2023.1207617","volume":"14","author":"N Capasso","year":"2023","unstructured":"Capasso N, Virgilio E, Covelli A, Giovannini B, Foschi M, Montini F, et al. Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review. Front Neurol. 2023;14:1207617.","journal-title":"Front Neurol"},{"key":"3474_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11910-020-01046-2","volume":"20","author":"B Zeydan","year":"2020","unstructured":"Zeydan B, Kantarci OH. Impact of age on multiple sclerosis disease activity and progression. Curr Neurol Neurosci. 2020;20:24.","journal-title":"Curr Neurol Neurosci"},{"key":"3474_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/ene.14191","volume":"27","author":"V Wyl","year":"2020","unstructured":"Wyl V, D\u00e9card BF, Benkert P, Lorscheider J, H\u00e4nni P, Lienert C, et al. Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on Immunomodulatory treatment. Eur J Neurol. 2020;27:1066\u201375.","journal-title":"Eur J Neurol"},{"key":"3474_CR4","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1177\/1352458518800815","volume":"25","author":"BL Conway","year":"2018","unstructured":"Conway BL, Zeydan B, Uyguno\u011flu U, Novotna M, Siva A, Pittock SJ, et al. Age is a critical determinant in recovery from multiple sclerosis relapses. Mult Scler J. 2018;25:1754\u201363.","journal-title":"Mult Scler J"},{"key":"3474_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22:568\u201377.","journal-title":"Lancet Neurol"},{"key":"3474_CR6","doi-asserted-by":"crossref","unstructured":"Zhu W, Xia Z. Treatment discontinuation in older people with multiple sclerosis. Curr Opin Neurol. 2024; 37:220-227.","DOI":"10.1097\/WCO.0000000000001272"},{"key":"3474_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-101819-092536","volume":"39","author":"S Majumder","year":"2021","unstructured":"Majumder S, McGeachy MJ. IL-17 in the pathogenesis of disease: good intentions gone awry. Annu Rev Immunol. 2021;39:1\u201320.","journal-title":"Annu Rev Immunol"},{"key":"3474_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2020.00947","volume":"11","author":"J Milovanovic","year":"2020","unstructured":"Milovanovic J, Arsenijevic A, Stojanovic B, Kanjevac T, Arsenijevic D, Radosavljevic G, et al. Interleukin-17 in chronic inflammatory neurological diseases. Front Immunol. 2020;11:947.","journal-title":"Front Immunol"},{"key":"3474_CR9","doi-asserted-by":"publisher","first-page":"14292","DOI":"10.1073\/pnas.1009234107","volume":"107","author":"M Mitsdoerffer","year":"2010","unstructured":"Mitsdoerffer M, Lee Y, J\u00e4ger A, Kim H-J, Korn T, Kolls JK, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci. 2010;107:14292\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"3474_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41590-019-0367-4","volume":"20","author":"S Majumder","year":"2019","unstructured":"Majumder S, Amatya N, Revu S, Jawale CV, Wu D, Rittenhouse N, et al. IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival. Nat Immunol. 2019;20:534\u201345.","journal-title":"Nat Immunol"},{"key":"3474_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","volume":"172","author":"JS Tzartos","year":"2008","unstructured":"Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous System-Infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146\u201355.","journal-title":"Am J Pathol"},{"key":"3474_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340.","journal-title":"J Exp Med"},{"key":"3474_CR13","doi-asserted-by":"publisher","first-page":"e57820","DOI":"10.1371\/journal.pone.0057820","volume":"8","author":"JR Christensen","year":"2013","unstructured":"Christensen JR, B\u00f6rnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-Helper, Th17- and activated B-Cells and correlates with progression. PLoS ONE. 2013;8:e57820.","journal-title":"PLoS ONE"},{"key":"3474_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2567.2008.02881.x","volume":"126","author":"ME Fransson","year":"2009","unstructured":"Fransson ME, Liljenfeldt LSE, Fagius J, T\u00f6tterman TH, Loskog ASI. The T-cell pool is anergized in patients with multiple sclerosis in remission. Immunology. 2009;126:92\u2013101.","journal-title":"Immunology"},{"key":"3474_CR15","first-page":"e200009","volume":"9","author":"RH Hansen","year":"2022","unstructured":"Hansen RH, Talbot J, Chow HH, Hansen MB, Buhelt S, Herich S, et al. Increased intrathecal activity of follicular helper T cells in patients with Relapsing-Remitting multiple sclerosis. Neurol: Neuroimmunol Neuroinflammation. 2022;9:e200009.","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"key":"3474_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jneuroim.2011.03.009","volume":"234","author":"Y Li","year":"2011","unstructured":"Li Y, Wang H, Long Y, Lu Z, Hu X. Increased memory Th17 cells in patients with neuromyelitis Optica and multiple sclerosis. J Neuroimmunol. 2011;234:155\u201360.","journal-title":"J Neuroimmunol"},{"key":"3474_CR17","doi-asserted-by":"publisher","first-page":"205521731989969","DOI":"10.1177\/2055217319899695","volume":"6","author":"S Kalra","year":"2020","unstructured":"Kalra S, Lowndes C, Durant L, Strange R, Al-Araji A, Hawkins CP, et al. Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only. Multiple Scler J Exp Transl Clin. 2020;6:2055217319899695.","journal-title":"Multiple Scler J Exp Transl Clin"},{"key":"3474_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune\u2013metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576\u201390.","journal-title":"Nat Rev Endocrinol"},{"key":"3474_CR19","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.exger.2013.09.003","volume":"48","author":"V Schmitt","year":"2013","unstructured":"Schmitt V, Rink L, Uciechowski P. The Th17\/Treg balance is disturbed during aging. Exp Gerontol. 2013;48:1379\u201386.","journal-title":"Exp Gerontol"},{"key":"3474_CR20","doi-asserted-by":"publisher","first-page":"13378","DOI":"10.18632\/aging.203119","volume":"13","author":"KM Merino","year":"2021","unstructured":"Merino KM, Jazwinski SM, Rout N. Th17-type immunity and inflammation of aging. Aging. 2021;13:13378\u20139.","journal-title":"Aging"},{"key":"3474_CR21","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s11011-019-00456-7","volume":"34","author":"T Flauzino","year":"2019","unstructured":"Flauzino T, Sim\u00e3o ANC, Pereira WL, de Alfieri CJ, Oliveira DF, Kallaur SR. Disability in multiple sclerosis is associated with age and inflammatory, metabolic and oxidative\/nitrosative stress biomarkers: results of multivariate and machine learning procedures. Metab Brain Dis. 2019;34:1401\u201313.","journal-title":"Metab Brain Dis"},{"key":"3474_CR22","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/eji.1830220431","volume":"22","author":"T Olsson","year":"1992","unstructured":"Olsson T, Sun J, Hillert J, H\u00f6jeberg B, Ekre H, Andersson G, et al. Increased numbers of T cells recognizing multiple Myelin basic protein epitopes in multiple sclerosis. Eur J Immunol. 1992;22:1083\u20137.","journal-title":"Eur J Immunol"},{"key":"3474_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-2567.2008.02837.x","volume":"125","author":"CJ Hedegaard","year":"2008","unstructured":"Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH. T helper cell type 1 (Th1), Th2 and Th17 responses to Myelin basic protein and disease activity in multiple sclerosis. Immunology. 2008;125:161\u20139.","journal-title":"Immunology"},{"key":"3474_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.21652","volume":"65","author":"L Durelli","year":"2009","unstructured":"Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon\u2010\u03b2. Ann Neurol. 2009;65:499\u2013509.","journal-title":"Ann Neurol"},{"key":"3474_CR25","doi-asserted-by":"crossref","unstructured":"Huber AK, Wang L, Han P, Zhang X, Ekholm S, Srinivasan A, et al. Dysregulation of the IL-23\/IL-17 axis and myeloid factors in secondary progressive MS. Neurology.2014;83:1500\u20137.","DOI":"10.1212\/WNL.0000000000000908"},{"key":"3474_CR26","doi-asserted-by":"publisher","first-page":"103092","DOI":"10.1016\/j.jaut.2023.103092","volume":"139","author":"MTM Monreal","year":"2023","unstructured":"Monreal MTM, Hansen BE, Iversen PF, Enevold C, \u00d8dum N, Sellebjerg F, et al. Citrullination of Myelin basic protein induces a Th17-cell response in healthy individuals and enhances the presentation of MBP85-99 in patients with multiple sclerosis. J Autoimmun. 2023;139:103092.","journal-title":"J Autoimmun"},{"key":"3474_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00726-021-03111-7","volume":"54","author":"V Martinsen","year":"2022","unstructured":"Martinsen V, Kursula P. Multiple sclerosis and Myelin basic protein: insights into protein disorder and disease. Amino Acids. 2022;54:99\u2013109.","journal-title":"Amino Acids"},{"key":"3474_CR28","doi-asserted-by":"publisher","first-page":"eabo6555","DOI":"10.1126\/scisignal.abo6555","volume":"16","author":"SK Revu","year":"2023","unstructured":"Revu SK, Yang W, Rajasundaram D, Brady A, Majumder S, Gaffen SL, et al. Human IL-17A protein production is controlled through a PIP5K1\u03b1-dependent translational checkpoint. Sci Signal. 2023;16:eabo6555.","journal-title":"Sci Signal"},{"key":"3474_CR29","doi-asserted-by":"publisher","first-page":"e20253","DOI":"10.1371\/journal.pone.0020253","volume":"6","author":"CJ Hedegaard","year":"2011","unstructured":"Hedegaard CJ, Enevold C, Sellebjerg F, Bendtzen K, Nielsen CH. Variation in NOD2 augments Th2- and Th17 responses to Myelin basic protein in multiple sclerosis. PLoS ONE. 2011;6:e20253.","journal-title":"PLoS ONE"},{"key":"3474_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/imm.12552","volume":"147","author":"AC Wing","year":"2016","unstructured":"Wing AC, Hygino J, Ferreira TB, Kasahara TM, Barros PO, Sacramento PM, et al. Interleukin-17\u2010 and interleukin\u201022\u2010secreting myelin\u2010specific CD4\u2009+\u2009T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients. Immunology. 2016;147:212\u201320.","journal-title":"Immunology"},{"key":"3474_CR31","doi-asserted-by":"crossref","unstructured":"Santini T, Chen C, Zhu W, Liou J-J, Walker E, Venkatesh S et al. Hippocampal subfields and thalamic nuclei associations with clinical outcomes in multiple sclerosis: an ultrahigh field MRI study. Mult Scler Relat Disord. 2024;105520.","DOI":"10.1016\/j.msard.2024.105520"},{"key":"3474_CR32","doi-asserted-by":"publisher","first-page":"e1565","DOI":"10.1212\/WNL.0000000000010460","volume":"95","author":"SN Levin","year":"2020","unstructured":"Levin SN, Riley CS, Dhand A, White CC, Venkatesh S, Boehm B, et al. Association of social network structure and physical function in patients with multiple sclerosis. Neurology. 2020;95:e1565\u201374.","journal-title":"Neurology"},{"key":"3474_CR33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/acn3.51314","volume":"8","author":"SN Levin","year":"2021","unstructured":"Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, et al. Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases. Ann Clin Transl Neur. 2021;8:918\u201328.","journal-title":"Ann Clin Transl Neur"},{"key":"3474_CR34","doi-asserted-by":"publisher","first-page":"685276","DOI":"10.3389\/fneur.2021.685276","volume":"12","author":"A Mani","year":"2021","unstructured":"Mani A, Santini T, Puppala R, Dahl M, Venkatesh S, Walker E, et al. Applying deep learning to accelerated clinical brain magnetic resonance imaging for multiple sclerosis. Front Neurol. 2021;12:685276.","journal-title":"Front Neurol"},{"key":"3474_CR35","doi-asserted-by":"publisher","first-page":"103433","DOI":"10.1016\/j.msard.2021.103433","volume":"57","author":"S Epstein","year":"2022","unstructured":"Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, et al. Vaccination against SARS-CoV-2 in neuroinflammatory disease: early safety\/tolerability data. Mult Scler Relat Disord. 2022;57:103433.","journal-title":"Mult Scler Relat Disord"},{"key":"3474_CR36","doi-asserted-by":"publisher","first-page":"103482","DOI":"10.1016\/j.msard.2021.103482","volume":"58","author":"E Levit","year":"2022","unstructured":"Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, et al. Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Mult Scler Relat Disord. 2022;58:103482.","journal-title":"Mult Scler Relat Disord"},{"key":"3474_CR37","doi-asserted-by":"publisher","first-page":"103648","DOI":"10.1016\/j.msard.2022.103648","volume":"59","author":"A Kever","year":"2022","unstructured":"Kever A, Walker ELS, Riley CS, Heyman RA, Xia Z, Leavitt VM. Association of personality traits with physical function, cognition, and mood in multiple sclerosis. Mult Scler Relat Disord. 2022;59:103648.","journal-title":"Mult Scler Relat Disord"},{"key":"3474_CR38","doi-asserted-by":"publisher","first-page":"e38495","DOI":"10.2196\/38495","volume":"9","author":"P Chikersal","year":"2022","unstructured":"Chikersal P, Venkatesh S, Masown K, Walker E, Quraishi D, Dey A, et al. Predicting multiple sclerosis outcomes during the COVID-19 Stay-at-home period: observational study using passively sensed behaviors and digital phenotyping. JMIR Ment Heal. 2022;9:e38495.","journal-title":"JMIR Ment Heal"},{"key":"3474_CR39","doi-asserted-by":"publisher","first-page":"103994","DOI":"10.1016\/j.msard.2022.103994","volume":"65","author":"DSSK Boorgu","year":"2022","unstructured":"Boorgu DSSK, Venkatesh S, Lakhani CM, Walker E, Aguerre IM, Riley C, et al. The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis. Mult Scler Relat Disord. 2022;65:103994.","journal-title":"Mult Scler Relat Disord"},{"key":"3474_CR40","doi-asserted-by":"publisher","first-page":"104235","DOI":"10.1016\/j.msard.2022.104235","volume":"68","author":"D Jakimovski","year":"2022","unstructured":"Jakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, et al. Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic. Mult Scler Relat Disord. 2022;68:104235.","journal-title":"Mult Scler Relat Disord"},{"key":"3474_CR41","doi-asserted-by":"publisher","first-page":"fcad300","DOI":"10.1093\/braincomms\/fcad300","volume":"6","author":"W Zhu","year":"2023","unstructured":"Zhu W, Chen C, Zhang L, Hoyt T, Walker E, Venkatesh S, et al. Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis. Brain Commun. 2023;6:fcad300.","journal-title":"Brain Commun"},{"key":"3474_CR42","doi-asserted-by":"publisher","first-page":"e45429","DOI":"10.2196\/45429","volume":"10","author":"C Riley","year":"2024","unstructured":"Riley C, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit E, et al. Impact of the COVID-19 pandemic on the personal networks and neurological outcomes of people with multiple sclerosis: Cross-Sectional and longitudinal Case-Control study. JMIR Public Heal Surveill. 2024;10:e45429.","journal-title":"JMIR Public Heal Surveill"},{"key":"3474_CR43","doi-asserted-by":"crossref","unstructured":"Boekel L, Atiqi S, Leeuw M, Hooijberg F, Besten YR, Wartena R et al. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands. Lancet Rheumatol. 2023.","DOI":"10.1016\/S2665-9913(23)00127-3"},{"key":"3474_CR44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, et al. Multiple sclerosis. Lancet. 2024;403:183\u2013202.","journal-title":"Lancet"},{"key":"3474_CR45","doi-asserted-by":"publisher","first-page":"1234572","DOI":"10.3389\/fragi.2023.1234572","volume":"4","author":"S Thakolwiboon","year":"2023","unstructured":"Thakolwiboon S, Mills EA, Yang J, Doty J, Belkin MI, Cho T, et al. Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. Front Aging. 2023;4:1234572.","journal-title":"Front Aging"},{"key":"3474_CR46","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2019","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2019;9:3116.","journal-title":"Front Immunol"},{"key":"3474_CR47","doi-asserted-by":"publisher","first-page":"e2023216118","DOI":"10.1073\/pnas.2023216118","volume":"118","author":"Z Huang","year":"2021","unstructured":"Huang Z, Chen B, Liu X, Li H, Xie L, Gao Y, et al. Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis. Proc Natl Acad Sci. 2021;118:e2023216118.","journal-title":"Proc Natl Acad Sci"},{"key":"3474_CR48","doi-asserted-by":"publisher","first-page":"103346","DOI":"10.1016\/j.jri.2021.103346","volume":"146","author":"A Han","year":"2021","unstructured":"Han A, Kim JY, Kwak-Kim J, Lee SK. Menopause is an inflection point of age-related immune changes in women. J Reprod Immunol. 2021;146:103346.","journal-title":"J Reprod Immunol"},{"key":"3474_CR49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41467-020-14396-9","volume":"11","author":"EJ M\u00e1rquez","year":"2020","unstructured":"M\u00e1rquez EJ, Chung C, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, et al. Sexual-dimorphism in human immune system aging. Nat Commun. 2020;11:751.","journal-title":"Nat Commun"},{"key":"3474_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/15321819.2019.1655649","volume":"40","author":"S Tahani","year":"2019","unstructured":"Tahani S, Dehghani L, Jahanbani-Ardakani H, Shaygannejad V, Fazli A, Hamidavi A, et al. Elevated serum level of IL-4 in neuromyelitis Optica and multiple sclerosis patients. J Immunoass Immunochem. 2019;40:555\u201363.","journal-title":"J Immunoass Immunochem"},{"key":"3474_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jneuroim.2006.07.014","volume":"181","author":"A Dressel","year":"2006","unstructured":"Dressel A, Vogelgesang A, Brinkmeier H, M\u00e4der M, Weber F. Glatiramer acetate-specific human CD8\u2009+\u2009T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment. J Neuroimmunol. 2006;181:133\u201340.","journal-title":"J Neuroimmunol"},{"key":"3474_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/135245859500100308","volume":"1","author":"M S\u00f6derstr\u00f6m","year":"1995","unstructured":"S\u00f6derstr\u00f6m M, Hillert J, Link J, Navikas V, Fredrikson S, Link H. Expression of IFN-\u03b3, IL-4, and TGF-\u03b2 in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Mult Scler. 1995;1:173\u201380.","journal-title":"Mult Scler"},{"key":"3474_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0165-5728(98)00002-2","volume":"86","author":"C McManus","year":"1998","unstructured":"McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol. 1998;86:20\u20139.","journal-title":"J Neuroimmunol"},{"key":"3474_CR54","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11064-018-2484-0","volume":"44","author":"D Mango","year":"2019","unstructured":"Mango D, Nistic\u00f2 R, Furlan R, Finardi A, Centonze D, Mori F. PDGF modulates synaptic excitability and Short-Latency afferent Inhibition in multiple sclerosis. Neurochem Res. 2019;44:726\u201333.","journal-title":"Neurochem Res"},{"key":"3474_CR55","doi-asserted-by":"publisher","first-page":"19112","DOI":"10.1523\/JNEUROSCI.2536-13.2013","volume":"33","author":"F Mori","year":"2013","unstructured":"Mori F, Rossi S, Piccinin S, Motta C, Mango D, Kusayanagi H, et al. Synaptic plasticity and PDGF signaling defects underlie clinical progression in multiple sclerosis. J Neurosci. 2013;33:19112\u20139.","journal-title":"J Neurosci"},{"key":"3474_CR56","doi-asserted-by":"publisher","first-page":"13829","DOI":"10.3390\/ijms232213829","volume":"23","author":"MM Melamud","year":"2022","unstructured":"Melamud MM, Ermakov EA, Boiko AS, Kamaeva DA, Sizikov AE, Ivanova SA, et al. Multiplex analysis of serum cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Int J Mol Sci. 2022;23:13829.","journal-title":"Int J Mol Sci"},{"key":"3474_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0165-5728(03)00085-7","volume":"137","author":"S Kastenbauer","year":"2003","unstructured":"Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung H-P, Pfister H-W. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol. 2003;137:210\u20137.","journal-title":"J Neuroimmunol"},{"key":"3474_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2011.11.006","volume":"38","author":"B Broux","year":"2012","unstructured":"Broux B, Pannemans K, Zhang X, Markovic-Plese S, Broekmans T, Eijnde BO, et al. CX3CR1 drives cytotoxic CD4\u2009+\u2009CD28\u2013\u2009T cells into the brain of multiple sclerosis patients. J Autoimmun. 2012;38:10\u20139.","journal-title":"J Autoimmun"},{"key":"3474_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.clim.2015.01.001","volume":"157","author":"K Blauth","year":"2015","unstructured":"Blauth K, Zhang X, Chopra M, Rogan S, Markovic-Plese S. The role of fractalkine (CX3CL1) in regulation of CD4\u2009+\u2009cell migration to the central nervous system in patients with relapsing\u2013remitting multiple sclerosis. Clin Immunol. 2015;157:121\u201332.","journal-title":"Clin Immunol"},{"key":"3474_CR60","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/1352458507084268","volume":"14","author":"D Galimberti","year":"2008","unstructured":"Galimberti D, Fenoglio C, Comi C, Scalabrini D, Riz MD, Leone M, et al. MDC\/CCL22 intrathecal levels in patients with multiple sclerosis. Mult Scler. 2008;14:547\u20139.","journal-title":"Mult Scler"},{"key":"3474_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jneuroim.2014.10.005","volume":"277","author":"J Burman","year":"2014","unstructured":"Burman J, Svensson E, Fransson M, Loskog ASI, Zetterberg H, Raininko R, et al. The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1\/Th2\/Th17 convention. J Neuroimmunol. 2014;277:153\u20139.","journal-title":"J Neuroimmunol"},{"key":"3474_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12974-019-1601-6","volume":"16","author":"G Lepennetier","year":"2019","unstructured":"Lepennetier G, Hracsko Z, Unger M, Griensven MV, Grummel V, Krumbholz M, et al. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. J Neuroinflammation. 2019;16:219.","journal-title":"J Neuroinflammation"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03474-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:03:30Z","timestamp":1749132210000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-025-03474-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03474-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.17.24304425","asserted-by":"object"}]},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}